Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 3, 2014, Pages 215-221

  Sher, David J ^a   Parikh, Ravi B ^b   Mays Jackson, Shawnda ^a   Punglia, Rinaa S ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cost effectiveness analysis; IMRT; Prostate cancer; Radiotherapy; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH STATUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; LOW RISK PATIENT; MALE; PREVALENCE; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; REIMBURSEMENT; STEREOTACTIC BODY RADIATION THERAPY; TRANSURETHRAL RESECTION; BLADDER; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; ECONOMICS; MONTE CARLO METHOD; PROBABILITY; PROSTATE TUMOR; RADIATION EXPOSURE; RADIOSURGERY; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER;

EID: 84904991288     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827a7d2a     Document Type: Article

References (20)

1. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280-1283.
2. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149.
3. Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. 2011;117: 1123-1135.
4. Teh BS, Ishiyama H, Mathews T, et al. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discov Med. 2010;10:255-262.
5. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517-1524.
6. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making. 1993;13:322-338.
7. Zelefsky MJ, Yamada Y, Pei X, et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology. 2011;77:986-990.
8. Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- To intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010;76: 1297-1304.
9. Friedland JL, Freeman DE, Masterson-McGary ME, et al. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009;8: 387-392.
10. Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20: 3199-3205.
11. Pham H, Song G, Badiozamani K, et al. Five-year outcome of stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) for patients with low-risk prostate. Cancer. 2010;78: S58. [Abstract].
12. Gold M, Siegel J, Russell L, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:425.
13. Centers for Medicare & Medicaid Services. 2011 Payment Schedules. http://www.wpsmedicare.com/part-b/fees/physician-fee-schedule/2012-fee-schedule.shtml. Accessed February 3, 2012.
14. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000;92:1731-1739.
15. CDC (Centers for Disease Control). Life Tables. Available at: Http://www.cdc.gov/nchs/products/life-tables.htm. Accesesd August 1, 2011.
16. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
17. Stewart ST, Lenert L, Bhatnagar V, et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347-355.
18. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review. IMRT Final Appraisal-Full Report. 2008. Available at: Http://www.icer-review.org/index.php/imrt.html. Accessed August 1, 2011.
19. Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008;299:898-899.
20. Toth C. Radiotherapy 2.0: robotics, image guidance, and increased precision. Centerline, Varian Medical Systems. 2011;2:1-2.